114 related articles for article (PubMed ID: 32008403)
21. BN nanospheres functionalized with mesoporous silica for enhancing CpG oligodeoxynucleotide-mediated cancer immunotherapy.
Zhang H; Cheng T; Lai L; Deng S; Yu R; Qiu L; Zhou J; Lu G; Zhi C; Chen J
Nanoscale; 2018 Aug; 10(30):14516-14524. PubMed ID: 30024003
[TBL] [Abstract][Full Text] [Related]
22. [Anti-tumor effect of two adjuvants of CpG ODN on leukemic tumor in mouse models].
He AL; Chen H; Zhang WG; Cao XM; Zhao WH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):1042-5. PubMed ID: 17956687
[TBL] [Abstract][Full Text] [Related]
23. Synergistic stimulation of antigen presenting cells via TLR by combining CpG ODN and poly(γ-glutamic acid)-based nanoparticles as vaccine adjuvants.
Shima F; Uto T; Akagi T; Akashi M
Bioconjug Chem; 2013 Jun; 24(6):926-33. PubMed ID: 23631730
[TBL] [Abstract][Full Text] [Related]
24. Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer.
Lubaroff DM; Karan D; Andrews MP; Acosta A; Abouassaly C; Sharma M; Krieg AM
Vaccine; 2006 Aug; 24(35-36):6155-62. PubMed ID: 16876291
[TBL] [Abstract][Full Text] [Related]
25. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
26. Encapsulation of two different TLR ligands into liposomes confer protective immunity and prevent tumor development.
Bayyurt B; Tincer G; Almacioglu K; Alpdundar E; Gursel M; Gursel I
J Control Release; 2017 Feb; 247():134-144. PubMed ID: 28069554
[TBL] [Abstract][Full Text] [Related]
27. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization.
Weiner GJ; Liu HM; Wooldridge JE; Dahle CE; Krieg AM
Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10833-7. PubMed ID: 9380720
[TBL] [Abstract][Full Text] [Related]
28. Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model.
Pilon-Thomas S; Li W; Briggs JJ; Djeu J; Mulé JJ; Riker AI
J Immunother; 2006; 29(4):381-7. PubMed ID: 16799333
[TBL] [Abstract][Full Text] [Related]
29. CpG oligonucleotides for immunotherapeutic treatment of neuroblastoma.
Miles SA; Sandler AD
Adv Drug Deliv Rev; 2009 Mar; 61(3):275-82. PubMed ID: 19186194
[TBL] [Abstract][Full Text] [Related]
30. Emerging patents in the therapeutic areas of glioma and glioblastoma.
Harris M; Svensson F; Kopanitsa L; Ladds G; Bailey D
Expert Opin Ther Pat; 2018 Jul; 28(7):573-590. PubMed ID: 29950117
[TBL] [Abstract][Full Text] [Related]
31. Anticancer patent landscape and technology assessment of Indian public-funded research institutes and organizations.
Dara A; Sangamwar AT
Expert Opin Ther Pat; 2014 Aug; 24(8):893-912. PubMed ID: 24898985
[TBL] [Abstract][Full Text] [Related]
32. Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy.
Heckelsmiller K; Beck S; Rall K; Sipos B; Schlamp A; Tuma E; Rothenfusser S; Endres S; Hartmann G
Eur J Immunol; 2002 Nov; 32(11):3235-45. PubMed ID: 12555669
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant Activity Enhanced by Cross-Linked CpG-Oligonucleotides in β-Glucan Nanogel and Its Antitumor Effect.
Miyamoto N; Mochizuki S; Fujii S; Yoshida K; Sakurai K
Bioconjug Chem; 2017 Feb; 28(2):565-573. PubMed ID: 27951636
[TBL] [Abstract][Full Text] [Related]
34. In vitro and in vivo evaluations of human papillomavirus type 16 (HPV16)-derived peptide-loaded dendritic cells (DCs) with a CpG oligodeoxynucleotide (CpG-ODN) adjuvant as tumor vaccines for immunotherapy of cervical cancer.
Wang HL; Xu H; Lu WH; Zhu L; Yu YH; Hong FZ
Arch Gynecol Obstet; 2014 Jan; 289(1):155-62. PubMed ID: 23912529
[TBL] [Abstract][Full Text] [Related]
35. CpG oligonucleotides as adjuvant in therapeutic vaccines against parasitic infections.
Zimmermann S; Dalpke A; Heeg K
Int J Med Microbiol; 2008 Jan; 298(1-2):39-44. PubMed ID: 17716944
[TBL] [Abstract][Full Text] [Related]
36. Cancer vaccine THERATOPE- Biomira.
Adis International Ltd
Drugs R D; 2003; 4(4):236-40. PubMed ID: 12848588
[TBL] [Abstract][Full Text] [Related]
37. [Studies on the enhancement of DC vaccine to mouse Lewis lung cancer by CpG oligonucleotides].
Du YC; Lin P; Zhang J; Lu YR; Ning QZ
Zhonghua Zhong Liu Za Zhi; 2005 Jan; 27(1):1-5. PubMed ID: 15771786
[TBL] [Abstract][Full Text] [Related]
38. Anti-Tumor Activity of Mannose-CpG-Oligodeoxynucleotides-Conjugated and Hepatoma Lysate-Loaded Nanoliposomes for Targeting Dendritic Cells
Yang X; Lai C; Liu A; Hou X; Tang Z; Mo F; Yin S; Lu X
J Biomed Nanotechnol; 2019 May; 15(5):1018-1032. PubMed ID: 30890232
[TBL] [Abstract][Full Text] [Related]
39. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
[TBL] [Abstract][Full Text] [Related]
40. Immunostimulatory CpG-DNA and PSA-peptide vaccination elicits profound cytotoxic T cell responses.
Maurer T; Pournaras C; Aguilar-Pimentel JA; Thalgott M; Horn T; Heck M; Heit A; Kuebler H; Gschwend JE; Nawroth R
Urol Oncol; 2013 Oct; 31(7):1395-401. PubMed ID: 21982682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
